证券代码：000566 证券简称：海南海药 公告编号：2025-062 海南海药股份有限公司 第十一届董事会第二十八次会议决议公告 本公司董事会及全体董事保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 海南海药股份有限公司（以下简称"公司"）第十一届董事会第二十八次会 议于 2025 年 10 月 29 日以通讯表决方式召开。本次会议于 2025 年 10 月 27 日以 电子邮件等方式送达了会议通知及文件。会议应到董事 9 人，实到董事 9 人，会 议的召开符合《公司法》和《公司章程》有关规定。经与会董事认真审议，表决 通过了如下议案： 一、 审议通过了《2025 年第三季度报告的议案》 具体内容详见同日刊载于巨潮资讯网（www.cninfo.com.cn）的《海南海药 股份有限公司 2025 年第三季度报告》。 表决结果：9 票同意，0 票反对，0 票弃权 二、审议通过了《关于调整第十一届董事会专门委员会委员的议案》 为进一步优化公司治理架构，提升决策科学性与治理效能，根据《公司章程》、 董事会各专门委员会议事规则的有关规定，董事会对四个专门委员会成员进行调 整，董事会各专门委员 ...

Financial Performance - The company's operating revenue for Q3 2025 was ¥189,408,874.14, a decrease of 10.36% compared to the same period last year[5] - The net profit attributable to shareholders was -¥84,000,150.87, with a year-to-date loss of -¥242,307,257.15[5] - The basic and diluted earnings per share were both -¥0.0647 for the current period[5] - Total operating revenue for the current period is CNY 639,683,832.92, a decrease of 20.5% compared to CNY 804,727,228.88 in the previous period[21] - The company reported a net loss of ¥262,645,523.82 for the current period, compared to a net loss of ¥313,678,925.17 in the previous period, representing an improvement of approximately 16.3%[22] - Operating profit (loss) for the current period was ¥-258,156,904.69, compared to ¥-305,059,177.96 in the previous period, indicating a reduction in losses by about 15.3%[22] - The company’s total comprehensive loss for the current period was ¥263,166,228.46, compared to a loss of ¥314,027,001.89 in the previous period, showing an improvement of about 16.3%[22] - Basic and diluted earnings per share were both reported at ¥-0.1868, an improvement from ¥-0.2275 in the previous period[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥5,790,095,764.09, down 5.29% from the end of the previous year[5] - The equity attributable to shareholders decreased by 47.01% to ¥278,371,317.30 compared to the previous year-end[5] - Current liabilities increased to CNY 4,359,829,200.30 from CNY 4,299,131,641.34, indicating a rise of 1.4%[19] - The company's total liabilities decreased to CNY 5,467,732,524.80 from CNY 5,523,151,531.94, a decrease of 1.0%[19] - The company's cash and cash equivalents decreased to CNY 259,728,662.81 from CNY 329,624,399.72, a decline of 21.1%[18] - Long-term equity investments slightly decreased to CNY 422,800,067.93 from CNY 429,519,914.71, a reduction of 1.6%[18] Cash Flow - Cash flow from operating activities for the year-to-date was ¥25,873,667.52, showing a significant improvement from -¥67,262,673.90 in the same period last year[9] - Cash flow from operating activities generated a net inflow of ¥25,873,667.52, a significant recovery from a net outflow of ¥67,262,673.90 in the previous period[23] - The company received cash from financing activities amounting to ¥2,303,823,616.13, compared to ¥3,048,072,741.84 in the previous period, reflecting a decrease of approximately 24.4%[24] - The company’s cash outflow from investing activities was ¥117,272,070.86, slightly down from ¥129,324,421.62 in the previous period[23] Expenses - Research and development expenses decreased by 52.86% to ¥27,335,705.41 compared to the previous year[9] - Sales expenses were reduced by 44.45% to ¥113,371,830.98, indicating effective control over market development costs[9] - The company's research and development expenses decreased to CNY 27,335,705.41 from CNY 57,982,852.49, a reduction of 52.9%[21] Shareholder Information - Total number of common shareholders at the end of the reporting period is 74,037[11] - The largest shareholder, Hainan Huadong Industrial Co., Ltd., holds 22.89% of shares, totaling 296,989,889 shares, with 148,494,944 shares pledged[11] - Shenzhen Nanfang Tongzheng Investment Co., Ltd. holds 10.28% of shares, totaling 133,346,318 shares, with 130,825,900 shares frozen[11] - Yunnan International Trust Co., Ltd. holds 5.26% of shares, totaling 68,295,512 shares[11] Legal and Financial Obligations - The company is pursuing legal action against Southern Tongzheng and others for a total debt of 311,169,942.04 RMB plus interest[15] - The company has a total of 101 properties mortgaged as collateral, with priority after certain banks[14] - The company has signed multiple agreements regarding debt transfer and compensation since December 2020[16] Other Financial Metrics - The company reported a significant increase in other payables by 75.84% to ¥1,898,667,712.80, primarily due to financial support from the controlling shareholder[9] - The company recorded a net investment income of ¥6,038,962.20, a recovery from a loss of -¥50,014,917.00 in the previous year[9] - The company's net investment income is CNY 6,038,962.20, a significant recovery from a loss of CNY 50,014,917.00 in the previous period[21] - The total assets decreased to CNY 5,790,095,764.09 from CNY 6,113,528,499.69, representing a decline of 5.3%[20] - The company's other comprehensive income after tax attributable to the parent company was ¥-520,704.64, compared to ¥-348,076.72 in the previous period, indicating a decline in comprehensive income[22]

Core Viewpoint - Hainan Haiyao reported a decline in revenue and significant net losses for the third quarter and the first three quarters of the year [1] Financial Performance - The company's revenue for the third quarter was 189 million, a year-on-year decrease of 10.36% [1] - The net loss for the third quarter amounted to 84 million [1] - For the first three quarters, the total revenue was 640 million, reflecting a year-on-year decline of 20.51% [1] - The net loss for the first three quarters reached 242 million [1]

Core Insights - The internet healthcare sector experienced a slight increase of 0.21% on October 29, with notable gains from companies like Jiangyu Pingmin, which rose by 6.29% [1] - The Shanghai Composite Index closed at 4016.33, up 0.7%, while the Shenzhen Component Index closed at 13691.38, up 1.95% [1] Company Performance - Jiangyu Pingmin (301017) closed at 11.99 with a gain of 6.29%, trading volume of 201,100 shares and a transaction value of 242 million [1] - Furuishi (300049) closed at 74.48, up 6.20%, with a trading volume of 150,500 shares and a transaction value of 1.104 billion [1] - Xingqi Eye Medicine (300573) closed at 82.01, increasing by 5.29%, with a trading volume of 309,400 shares and a transaction value of 2.518 billion [1] - Other notable performers include Maidi Technology (603990) with a 2.98% increase and a transaction value of 384 million, and Hanhui Technology (300007) with a 2.68% increase and a transaction value of 1.402 billion [1] Market Dynamics - The internet healthcare sector saw a net outflow of 1.125 billion from institutional investors, while retail investors contributed a net inflow of 926 million [2][3] - The overall market sentiment indicated a mixed response, with some stocks experiencing significant declines, such as Jiayuan Technology (301117) which fell by 13.29% [2] - The trading activity highlighted a divergence in investor behavior, with institutional investors pulling back while retail investors remained active [2][3]

证券日报网讯海南海药（000566）10月28日在互动平台回答投资者提问时表示，截至2025年10月20日， 公司股东户数为77，518户。 ...

证券日报网讯海南海药（000566）10月28日在互动平台回答投资者提问时表示，公司产品出口主要集中 在东南亚地区，同时公司正在积极开发南美市场，目前处于前期资料申报与审批阶段。未来公司将不断 加强对"一带一路"国家市场开拓力度，提升国际化经营能力。 ...

Core Viewpoint - Hainan Haiyao is focusing on expanding its international market presence, particularly in Southeast Asia and South America, while enhancing its capabilities in line with the Belt and Road Initiative [1] Group 1 - The company's product exports are primarily concentrated in Southeast Asia [1] - Hainan Haiyao is actively developing the South American market, currently in the preliminary documentation and approval stage [1] - The company aims to strengthen its market development efforts in countries participating in the Belt and Road Initiative [1]

Core Viewpoint - The company is focusing on expanding its international market presence, particularly in Southeast Asia and South America, while enhancing its capabilities in the "Belt and Road" initiative countries [1] Group 1 - The company's product exports are primarily concentrated in Southeast Asia [1] - The company is actively developing the South American market, currently in the preliminary documentation and approval stage [1] - The company aims to strengthen its market development efforts in countries involved in the "Belt and Road" initiative [1]

Core Viewpoint - The company primarily exports its products to Southeast Asia and is actively developing the South American market, currently in the preliminary documentation and approval stage [1] Group 1 - The company has a certain proportion of overseas markets [1] - The company received inquiries about exports to EU countries [1] - The company is focusing on expanding its market presence in South America [1]

Core Viewpoint - Hainan Haiyao disclosed that over 5% shareholder Southern Tongzheng's shares are subject to judicial auction, which may impact the company's shareholding structure but will not change control [1] Group 1: Shareholder Auction Details - Southern Tongzheng's pledged shares of Hainan Haiyao amount to 130.8259 million shares, with 98.11% of these shares being auctioned [1] - The auction represents 10.08% of Hainan Haiyao's total share capital [1] - The second auction for 123.8259 million shares is scheduled for November 1-2, while the first auction for 7 million shares is set for November 16-17 [1] Group 2: Impact on Shareholding - If the auctions are successful, Southern Tongzheng's holdings will decrease to 2.520418 million shares, representing 0.19% of the total shares [1] - The company emphasizes that the auction results are uncertain and will not lead to a change in actual control or adverse effects on the company [1] - Hainan Haiyao will continue to disclose updates regarding the auction process [1]